What is Barclays's price target for BLUE?

Barclays's latest stated price target for bluebird bio Inc. (BLUE) is $8, from its action on Jun 1, 2023.

What is Barclays's rating on BLUE?

Barclays rates BLUE Overweight, a bullish rating, as of Jun 1, 2023.

When did Barclays last change its view on BLUE?

On Jun 1, 2023, Barclays upgrades to Overweight from Equal Weight, price target $7 to $8.

Barclays BLUE price target and rating history

Barclays rates bluebird bio Inc. (BLUE) Overweight with a $8 price target, as of its latest action on Jun 1, 2023. It has published 4 rating actions on BLUE since November 2021, including 2 upgrades and 1 downgrade.

Current rating: Overweight
Price target: $8
Median target, all firms: Too few
Actions on BLUE: 4

Barclays price target on BLUE

Barclays price target on BLUE, each point a stated target, November 2021 to June 2023.

Every Barclays rating on BLUE

Jun 1, 2023
UpgradeBarclays upgrades to Overweight from Equal Weight, price target $7 to $8
Aug 5, 2022
UpgradeBarclays upgrades to Equal Weight from Underweight
Mar 7, 2022
DowngradeBarclays downgrades to Underweight from Equal-Weight, price target $13 to $4
Nov 8, 2021
ReiterateBarclays cuts its price target to $13 from $20, keeps Equal-Weight

Questions about Barclays and BLUE

What is Barclays's price target for BLUE?: Barclays's latest stated price target for bluebird bio Inc. (BLUE) is $8, from its action on Jun 1, 2023.
What is Barclays's rating on BLUE?: Barclays rates BLUE Overweight, a bullish rating, as of Jun 1, 2023.
When did Barclays last change its view on BLUE?: On Jun 1, 2023, Barclays upgrades to Overweight from Equal Weight, price target $7 to $8.

More BLUE rating histories

All Barclays ratings BLUE news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.